Showing 2,461 - 2,480 results of 2,811 for search '"pharmaceutical company"', query time: 0.76s Refine Results
  1. 2461

    Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States by Othman, Noordin, Vitry, Agnes I., Roughead, Elizabeth E.

    Published 2010
    “…Background Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. …”
    Get full text
    Article
  2. 2462

    To determine and examine the prospect and feasibility study of anti-cancer drugs for local production in Bangladesh by Islam, Mohd Aminul, Azad, Abdul Kalam

    Published 2013
    “…‘Anti-Cancer Drugs’ has a good demand in the market and nearly 95% to 98% pharmaceutical companies are used to import this product from the foreign countries (according to anti-cancer Market). …”
    Get full text
    Get full text
    Article
  3. 2463

    Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. by Darbyshire, J, Foulkes, M, Peto, R, Duncan, W, Babiker, A, Collins, R, Hughes, M, Peto, T, Walker, A

    Published 2000
    “…SEARCH STRATEGY: Investigators and pharmaceutical companies were contacted, and MEDLINE searches were supplemented by searching conference abstracts. …”
    Journal article
  4. 2464

    Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. by Darbyshire, J, Foulkes, M, Peto, R, Duncan, W, Babiker, A, Collins, R, Hughes, M, Peto, T, Walker, A

    Published 2000
    “…SEARCH STRATEGY: Investigators and pharmaceutical companies were contacted, and MEDLINE searches were supplemented by searching conference abstracts. …”
    Journal article
  5. 2465

    Marketing madness by Anne Zimmerman

    Published 2020-03-01
    “…It is possible that pharmaceutical companies’ lack of access to the data for detailing could make more room for generic drug sales. …”
    Get full text
    Article
  6. 2466
  7. 2467

    HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer by Avisek Majumder

    Published 2023-10-01
    “…As HER3 cannot be targeted through its KD with small-molecule kinase inhibitors via the conventional method, pharmaceutical companies have used various other approaches, including blocking either the ligand-binding domain or extracellular domain for dimerization with other receptors. …”
    Get full text
    Article
  8. 2468
  9. 2469

    Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review by Kulier Regina, Helmerhorst Frans M, Maitra Nandita, Gülmezoglu A Metin

    Published 2004-06-01
    “…Eighteen were sponsored by pharmaceutical companies and in only 5 there was an attempt for blinding. …”
    Get full text
    Article
  10. 2470

    Az Ipar 4.0 hatásai az ellátási láncok mentén – a gyógyszeripar példája by Barbara Kitti Fetter, Gyula Zilahy

    Published 2021-01-01
    “…In the first part of our research, in addition to the findings of the literature, we conducted exploratory in-depth interviews with represen-tatives of three large Hungarian pharmaceutical companies. In the second part of the research, we uti-lized the knowledge gained during the in-depth interviews with the help of a structured questionnaire.The most important result of our research is that as a result of Industry 4.0 developments, monopolis-tic presence of large enterprises will most likely increase in the pharmaceutical industry. …”
    Get full text
    Article
  11. 2471

    India-EU relations in health services: prospects and challenges by Chanda Rupa

    Published 2011-02-01
    “…However, several opportunity segments exist, namely: (i) Telemedicine; (ii) Clinical trials and research in India for EU-based pharmaceutical companies; (iii) Medical transcriptions and back office support; (iv) Medical value travel; and (v) Collaborative ventures in medical education, research, training, staff deployment, and product development. …”
    Get full text
    Article
  12. 2472
  13. 2473

    Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China by Zhang Y, Liu X, Yang L, Zhang G, Gu Z, Chen Z, Sun J

    Published 2020-10-01
    “…The observations identified key intervention areas including continued efforts to make the novel effective medicines affordable and to strengthen the legislative protection for off-label use of evidence-based medicines; increase incentives for pharmaceutical companies to expand indications of established medicines based on the evidence; implement public initiatives to support the use of repurposed medicines for diseases with major public health significance, and scale up good practices from local pilots to create a coordinated multi-sourced financing model. …”
    Get full text
    Article
  14. 2474

    Limited accessibility to designs and results of Japanese large-scale clinical trials for cardiovascular diseases by Tsutani Kiichiro, Ueshima Kenji, Sawata Hiroshi

    Published 2011-04-01
    “…Most of the larger-scale trials were funded by private organizations such as pharmaceutical companies. The designs and results of 13 trials were not disclosed.…”
    Get full text
    Article
  15. 2475

    Hormone Replacement Therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain by Cantero María, Llaguno Marta, Chilet-Rosell Elisa, Alonso-Coello Pablo

    Published 2010-03-01
    “…</p> <p>Conclusions</p> <p>Even though pharmaceutical companies have committed themselves to compliance with codes of good practice, deficiencies were observed regarding the identification, information and promotion of HRT medications on their web pages. …”
    Get full text
    Article
  16. 2476

    Funding and infrastructure among large-scale clinical trials examining cardiovascular diseases in Japan: evidence from a questionnaire survey by Sawata Hiroshi, Tsutani Kiichiro

    Published 2011-11-01
    “…All of the foundations involved in conducting clinical trials, where funding sources were specified, were funded by private organizations such as pharmaceutical companies. All of the clinical trials with a cost of JPY 300 million (USD 3.27 million) or more were funded by private organizations, and none were funded solely by public agencies. …”
    Get full text
    Article
  17. 2477

    Understanding of research: a Sri Lankan perspective by Siriwardhana Chesmal, Athukorale Manjula, Lekamwattage Manura, Hewage Suwin, Siribaddana Sisira, Sumathipala Athula, Munasinghe Kumudu, Sumathipala Kethakie, Murray Joanna, Prince Martin

    Published 2010-04-01
    “…Doctors, health professionals, health institutions, scientists, professionals, businessmen, pharmaceutical companies, students, teachers were identified as people who conduct research.…”
    Get full text
    Article
  18. 2478

    Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States by Vitry Agnes I, Othman Noordin, Roughead Elizabeth E

    Published 2010-05-01
    “…<p>Abstract</p> <p>Background</p> <p>Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. …”
    Get full text
    Article
  19. 2479
  20. 2480

    The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis by The Inaugural Amyloidosis Forum Panelists, Isabelle Lousada

    Published 2020-09-01
    “…Main Body The inaugural Amyloidosis Forum was convened at FDA on 12 November 2019 and led by a multidisciplinary panel of physicians, health outcomes professionals, and representatives from the FDA, ARC, and pharmaceutical companies. Patients provided important perspectives on the pathway to diagnosis, challenges of rigorous treatment, and the burden of disease. …”
    Get full text
    Article